ZIOPHARM Oncology (ZIOP) Stock Price Up 8.3%

Share on StockTwits

ZIOPHARM Oncology Inc. (NASDAQ:ZIOP) rose 8.3% on Wednesday . The stock traded as high as $2.50 and last traded at $2.47. Approximately 1,505,606 shares were traded during mid-day trading, an increase of 8% from the average daily volume of 1,392,085 shares. The stock had previously closed at $2.28.

Separately, BidaskClub raised ZIOPHARM Oncology from a “strong sell” rating to a “sell” rating in a research report on Saturday. Three investment analysts have rated the stock with a sell rating, two have given a hold rating and one has assigned a buy rating to the company’s stock. ZIOPHARM Oncology currently has an average rating of “Hold” and a consensus target price of $5.25.

The stock has a market capitalization of $337.44 million, a price-to-earnings ratio of -4.66 and a beta of 1.85.

ZIOPHARM Oncology (NASDAQ:ZIOP) last issued its earnings results on Wednesday, August 8th. The biotechnology company reported ($0.12) earnings per share for the quarter, hitting the Thomson Reuters’ consensus estimate of ($0.12). On average, equities research analysts predict that ZIOPHARM Oncology Inc. will post -0.5 EPS for the current year.

Several hedge funds and other institutional investors have recently modified their holdings of ZIOP. BlackRock Inc. boosted its position in shares of ZIOPHARM Oncology by 8.5% in the second quarter. BlackRock Inc. now owns 9,167,740 shares of the biotechnology company’s stock worth $27,686,000 after buying an additional 717,804 shares during the period. Russell Investments Group Ltd. purchased a new stake in shares of ZIOPHARM Oncology in the first quarter worth about $911,000. UBS Group AG boosted its position in shares of ZIOPHARM Oncology by 35.3% in the first quarter. UBS Group AG now owns 872,376 shares of the biotechnology company’s stock worth $3,420,000 after buying an additional 227,812 shares during the period. Bank of America Corp DE boosted its position in shares of ZIOPHARM Oncology by 198.1% in the second quarter. Bank of America Corp DE now owns 99,565 shares of the biotechnology company’s stock worth $301,000 after buying an additional 201,063 shares during the period. Finally, Vident Investment Advisory LLC boosted its position in shares of ZIOPHARM Oncology by 46.8% in the second quarter. Vident Investment Advisory LLC now owns 587,255 shares of the biotechnology company’s stock worth $1,774,000 after buying an additional 187,195 shares during the period. 39.32% of the stock is owned by institutional investors.

ILLEGAL ACTIVITY NOTICE: “ZIOPHARM Oncology (ZIOP) Stock Price Up 8.3%” was originally published by Week Herald and is the sole property of of Week Herald. If you are viewing this report on another site, it was copied illegally and republished in violation of U.S. & international copyright & trademark laws. The legal version of this report can be accessed at https://weekherald.com/2018/11/08/ziopharm-oncology-ziop-stock-price-up-8-3.html.

About ZIOPHARM Oncology (NASDAQ:ZIOP)

ZIOPHARM Oncology, Inc, a biotechnology company, focuses on acquiring, developing, and commercializing a portfolio of immuno-oncology therapies for treating heterogenous solid tumors and unknown antigens. The company develops two immuno-oncology platform technologies, including Controlled IL-12, which delivers interleukin 12 or IL-12, a master regular of the immune system, in a controlled and safe manner to focus the patient's immune system to cancer; and Sleeping Beauty (SB), which is based on the genetic engineering of T-cells using the (SB) system to rapidly reprogram T-cells outside of the body for infusion.

Featured Story: Do Tariffs Work?

Receive News & Ratings for ZIOPHARM Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ZIOPHARM Oncology and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply